Notice2021-19221
Agency Information Collection Activities; Proposed Collection; Comment Request; Reclassification Petitions for Medical Devices
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
September 7, 2021
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA, Agency, or we) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection associated with reclassification of medical devices.
Full Text
<html>
<head>
<title>Federal Register, Volume 86 Issue 170 (Tuesday, September 7, 2021)</title>
</head>
<body><pre>
[Federal Register Volume 86, Number 170 (Tuesday, September 7, 2021)]
[Notices]
[Pages 50132-50134]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2021-19221]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2013-N-1529]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Reclassification Petitions for Medical Devices
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA, Agency, or we) is
announcing an opportunity for public comment on the proposed collection
of certain information by the Agency. Under the Paperwork Reduction Act
of 1995 (PRA), Federal Agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on information collection
associated with reclassification of medical devices.
DATES: Submit either electronic or written comments on the collection
of information by November 8, 2021.
ADDRESSES: You may submit comments as follows. Please note that late,
untimely filed comments will not be considered. Electronic comments
must be submitted on or before November 8, 2021. The <a href="https://www.regulations.gov">https://www.regulations.gov</a> electronic filing system will accept comments until
11:59 p.m. Eastern Time at the end of November 8, 2021. Comments
received by mail/hand delivery/courier (for written/paper submissions)
will be considered timely if they are postmarked or the delivery
service acceptance receipt is on or before that date.
Electronic Submissions
Submit electronic comments in the following way:
<bullet> Federal eRulemaking Portal: <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to <a href="https://www.regulations.gov">https://www.regulations.gov</a>
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
<bullet> If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
<bullet> Mail/Hand delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
<bullet> For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2013-N-1529 for ``Agency Information Collection Activities;
Proposed Collection; Comment Request; Reclassification Petitions for
Medical Devices.'' Received comments, those filed in a timely manner
(see ADDRESSES), will be placed in the docket and, except for those
submitted as ``Confidential Submissions,'' publicly viewable at <a href="https://www.regulations.gov">https://www.regulations.gov</a> or at the Dockets Management Staff between 9 a.m.
and 4 p.m., Monday through Friday, 240-402-7500.
<bullet> Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on <a href="https://www.regulations.gov">https://www.regulations.gov</a>.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: <a href="https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf">https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf</a>.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to <a href="https://www.regulations.gov">https://www.regulations.gov</a> and insert the docket number, found in brackets in
the
[[Page 50133]]
heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852, 240-402-7500.
FOR FURTHER INFORMATION CONTACT: Amber Sanford, Office of Operations,
Food and Drug Administration, Three White Flint North, 10A-12M, 11601
Landsdown St., North Bethesda, MD 20852, 301-796-8867,
<a href="/cdn-cgi/l/email-protection#f7a7a5b6a483969191b7919396d99f9f84d9909881"><span class="__cf_email__" data-cfemail="421210031136232424022426236c2a2a316c252d34">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3521), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Reclassification Petitions for Medical Devices
OMB Control Number 0910-0138--Extension
The Federal Food, Drug, and Cosmetic Act (FD&C Act) establishes the
following three categories (classes) of devices, reflecting the
regulatory controls needed to provide reasonable assurance of their
safety and effectiveness: Class I (general controls), class II (special
controls), and class III (premarket approval) (section 513(a)(1) of the
FD&C Act (21 U.S.C. 360c(a)(1)). To change a device classification, FDA
can initiate a reclassification, or an interested person can petition
FDA to reclassify a device based on new information (section 513(e) of
the FD&C Act). On July 9, 2012, the Food and Drug Administration Safety
and Innovation Act (FDASIA) was enacted, changing the reclassification
process under section 513(e) of the FD&C Act from rulemaking to an
administrative order process. To reclassify a device under section
513(e) of the FD&C Act, FDA must do the following before making the
reclassification final: (1) Publish a proposed order in the Federal
Register which includes the proposed reclassification and a summary of
the valid scientific evidence that supports the reclassification, (2)
convene a device classification panel meeting, and (3) consider
comments from the relevant public docket.
FDASIA also amended the provisions of the FD&C Act authorizing FDA
to require submission of a premarket approval application (PMA) for a
preamendments class III device (referred to as a ``call for PMAs'').
Preamendments devices are devices that were in commercial distribution
before the enactment of the 1976 Amendments. Under the FD&C Act,
preamendments devices classified into class III may be marketed upon
clearance of a 510(k) submission, and submission of a PMA is not
required until FDA has issued a final order requiring premarket
approval (section 515(b) of the FD&C Act (21 U.S.C. 360e(b)). As
amended by FDASIA, the FD&C Act requires that FDA, in its call for
PMAs, publish a proposed order in the Federal Register, hold a
classification panel meeting, and consider comments on the proposed
order (section 515(b) of the FD&C Act, as amended by FDASIA).
Under the FD&C Act, FDA's call for PMAs must, among other things,
contain an opportunity for interested persons to request a change in
the classification of the device based on new information (section
515(b)(2) of the FD&C Act). After consideration of comments on the
proposed order and findings, FDA must either: (1) Finalize the call for
PMAs by issuing an administrative order requiring approval of a PMA and
publishing in the Federal Register findings with respect to: (i) The
degree of risk of illness or injury designed to be eliminated or
reduced by requiring the device to have an approved PMA or a declared
completed product development protocol and (ii) the benefit to the
public from the use of the device; or (2) publish a notice in the
Federal Register terminating the proceeding and initiate a
reclassification proceeding based on new information (section 515(b)(3)
of the FD&C Act, as amended by FDASIA; see section 513(e) of the FD&C
Act).
The FD&C Act, as amended by FDASIA, now requires the use of
administrative orders, rather than rulemaking, when FDA calls for PMAs
for a preamendments device remaining in class III (section 515(b) of
the FD&C Act, as amended by FDASIA).
FDA refers to a device that was not in commercial distribution
before the 1976 Amendments as a postamendments device. Postamendments
devices are classified automatically into class III by statute, without
any rulemaking process (section 513(f)(1) of the FD&C Act). A
postamendments device remains in class III and is subject to the PMA
requirements unless and until: (1) FDA reclassifies the device into
class I or II; (2) FDA issues an order classifying the device into
class I or II via the De Novo classification process (see section
513(f)(2) of the FD&C Act); or (3) FDA issues an order finding the
device to be substantially equivalent to a predicate device that does
not require the filing of a PMA (see section 513(i) of the FD&C Act).
FDA may initiate, or the manufacturer or importer of a device may
petition for, the reclassification of a postamendments device
classified into class III by operation of law (section 513(f)(3) of the
FD&C Act). This FDA-initiated reclassification process consists of a
proposed reclassification order, optional panel consultation, and a
final reclassification order published in the Federal Register
following consideration of comments and any panel recommendations or
comments (Sec. 860.134(c) (21 CFR 860.134(c))). The reclassification
order may, as appropriate, establish special controls to provide
reasonable assurance of the safety and effectiveness of the device
(Sec. 860.134(d)).
Under the 1976 Amendments, Congress classified all those devices
previously regulated as new drugs into class III (generally referred to
as transitional devices). Under the FD&C Act, FDA may initiate, or the
manufacturer or importer of a device may petition for, the
reclassification of a transitional device remaining in class III
(section 520(l)(2) of the FD&C Act (21 U.S.C. 360j(l)(2)). The process
for reclassification of transitional devices initiated by FDA is
detailed in 21 CFR 860.136(c). This process consists of a proposed
reclassification order, optional panel consultation, and a final
[[Page 50134]]
reclassification order published in the Federal Register following
consideration of comments and any panel recommendations or comments.
We estimate the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of
21 CFR section; information collection activity Number of responses per Total annual Average burden Total hours
respondents respondent responses per response
--------------------------------------------------------------------------------------------------------------------------------------------------------
Sec. 860.123; supporting data for reclassification petitions..... 6 1 6 497 2,982
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
Based on a review of the information collection since our last
request for OMB approval, we have made no adjustments to our burden
estimate.
Dated: August 31, 2021.
Lauren K. Roth,
Acting Principal Associate Commissioner for Policy.
[FR Doc. 2021-19221 Filed 9-3-21; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on September 7, 2021.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.